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Abstract: Cortical spreading depression (CSD) involves a slowly-propagating depolarization 
wave in the cortex, which can appear in numerous pathophysiological conditions, such as 
migraine with aura, stroke, and traumatic brain injury. Neurons and glial cells are also depolarized 
transiently during the phenomena. CSD is followed by a massive increase in glutamate release 
and by changes in the brain microcirculation. The aim of this study was to investigate the effects 
of two N-methyl-D-aspartate receptor antagonists, endogenous kynurenic acid (KYNA) and 
dizocilpine, on CSD and the related blood–brain barrier (BBB) permeability in rats. In intact 
animals, KYNA hardly crosses the BBB but has some positive features as compared with its 
precursor L-Kynurenine, which is frequently used in animal studies (KYNA cannot be metabolized 
to excitotoxic agents such as 3-hydroxy-L-kynurenine and quinolinic acid). We therefore 
investigated the possible effects of peripherally administered KYNA. Repetitive CSD waves were 
elicited by the application of 1 M KCl solution to the cortex. Direct current-electrocorticograms 
were measured for 1 hour. Four parameters of the waves were compared. Evans blue dye and 
fluorescent microscopy were used to study the possible changes in the permeability of the BBB. 
The results demonstrated that N-methyl-D-aspartate receptor antagonists can reduce the number 
of CSD waves and decrease the permeability of the BBB during CSD. These results suggest that 
KYNA itself or its derivatives may offer a new approach in the therapy of migraines.
Keywords: blood–brain barrier, cortical spreading depression, glutamate receptors, kynurenic 
acid, kynurenines, NMDAR
Introduction
Cortical spreading depression (CSD), discovered by Leao in 1944, is a slowly-
propagating, transient, negative direct current (DC) shift accompanied by depressed 
neuronal bioelectrical activity. The main event during CSD is the depolarization of a 
critical mass of brain tissue and a massive elevation in glutamate release associated 
with an increase in extracellular potassium ion concentration, water influx into the 
cells, and shrinkage of the extracellular space1–4 There are also changes in immediate 
early genes, neurotransmitters, growth factors, etc.5
Some years ago, it was observed that a high glutamate level reduced the function 
of the blood–brain barrier (BBB) via endothelium-expressed N-methyl-D-aspartate 
receptor (NMDAR)-dependent occludin phosphorylation.6 Moreover, CSD initiates 
disruption of the BBB via a matrix metalloprotease-dependent mechanism.7
Despite intensive research, the exact pathomechanism of migraine and its 
connection with CSD are not completely understood. Various results have indicated 
that CSD is associated with changes in the diameter of blood vessels in the cortical 
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surface,8 while other authors have described it as a 
phenomenon following acute cortical injury, including 
brain ischemia,9 and yet others consider it to be an 
electrophysiological substrate of migraine aura, which may 
induce headache.10,11
In recent years, we have studied the effects of 
L-Kynurenine (KYN) and some derivatives of kynurenic 
acid (KYNA) on different animal models of migraine.12–14 
It was found, for instance, that KYN suppressed CSD 
waves and could mitigate some of the labeling thought to be 
experimental signs of migraine (eg, c-fos immunoreactivity 
and neuronal nitric oxide synthase).12–15 It is widely accepted 
that KYN (the precursor of KYNA) can readily cross the 
BBB, but that KYNA itself, the only known endogenous 
NMDAR antagonist, hardly crosses the BBB at all,16 whereas 
there is evidence that peripherally administered KYNA can 
penetrate the intact BBB.17,18 Furthermore, published data 
indicate that CSD results in a disruption of the BBB.7,19 
Since NMDARs play a decisive role in the generation and 
propagation of CSD,3,20 and data are accumulating which 
suggest that endogenous KYNA may act as a modulator 
at various levels of the pathomechanism of migraine,21 it 
seemed plausible to study the effects on CSD of exogenously 
administered KYNA.
Although little is yet known about the connections 
between migraine, CSD, and changes in BBB permeability, 
such a relationship appears more than probable. Accordingly, 
we have now studied the KCl-induced CSD and changes in 
BBB permeability after the administration of KYNA and, as 
a positive control, dizocilpine (MK-801; a well-known non-
competitive antagonist of NMDARs) in order to elucidate 
whether or not these neuroactive molecules act in parallel 
on CSD and BBB permeability.
Materials and methods
Animals
The National Institutes of Health principles of animal care 
and the protocol for animal care, approved by both the 
Hungarian Health Committee (1998) and the European 
Communities Council Directive (86/609/EEC), were 
strictly followed. Every effort was made to limit the num-
ber of animals and their suffering. Fifteen male Wistar rats 
(270 ± 21 g) (Charles River, Wilmington, MA, USA) were 
used for the electrophysiological portion of this study, 
and an additional 17 for histology. The animals were kept 
under 12-hour light and 12-hour dark conditions and were 
raised with free access to water and food pellets. The room 
temperature was 22°C ± 1°C.
Surgery
All the procedures were carried out under deep nembutal 
anesthesia, achieved with a dose of 60 mg/kg Euthasol® 
(AST Farma, Oudewater, the Netherlands), followed by 
20 mg/kg hourly. A trachea cannula was inserted and the 
head of the animals was fixed in a stereotaxic frame (David 
Kopf Instruments, Tujunga, CA, USA). After exposure of 
the skull, two holes were drilled through the left side of the 
skull under cooling with saline; one hole facilitated DC-
electrocorticogram (DC-ECoG) recording above the primary 
somatosensory cortex (3 mm caudally; 5 mm laterally from 
the bregma) and the other allowed access for the induction 
of CSD (7 mm caudally and 5 mm laterally) (Figure 1). The 
dura mater and arachnoidea were carefully removed from 
the posterior hole.
Electrophysiology
A glass microelectrode filled with 150 mM saline (resistance 
0.8–1.2 MΩ) connected to an Ag/AgCl wire was inserted into 
the cortex to a depth of 1000–1200 µm, corresponding to 
cortical layer V. The control group (n = 5) received 1 mL of 
phosphate buffer (0.2 M, pH = 7.4). The KYNA group (n = 5) 
was treated with 300 mg/kg KYNA (Sigma-Aldrich, St Louis, 
MO, USA) dissolved in 400 µL of 1 M NaOH and 600 µL 
of phosphate buffer. MK-801 (Tocris Bioscience, Bristol, 
UK) was dissolved in phosphate buffer and administered at 
2 mg/kg to the animals in the positive control group (n = 5). 
Figure 1 Explanatory figure relating to the experimental protocol.
Notes: Two holes were drilled through the left side of the skull, one for KCl 
application (1) and the other for direct current-electrocorticogram recording (2). 
The two holes were also drilled in the histological part of this study. The parallel black 
lines represent the location of the analyzed sections. The rectangles on the right side 
of the picture show the sites of the digital images captured after Evans blue staining.
Abbreviation: KCl, potassium chloride.
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All of these drugs were injected intraperitoneally. The 
cortex was allowed to recover for 30 minutes following the 
surgical preparation and treatment. CSD was induced by 
placing a cotton ball (diameter 1 mm) soaked with 1 M KCl 
solution on the cortex through the posterior hole. To keep 
the cotton ball moist, it was impregnated with 5 µL of KCl 
solution every 15 minutes. The DC-ECoG was measured for 
1 hour. Following offline data processing with laboratory-
developed software, four parameters of the CSD waves were 
compared between groups: the numbers of CSD episodes 
per hour, the peak-to-peak amplitude of the waves, the time 
at half-amplitude, and the area of the waves, calculated via 
integration. All of these parameters were measured for all 
waves and then averaged within an animal. The two-sample 
t-test statistical analyses were carried out with Origin 
8.1 software (OriginLab, Northampton, MA, USA).
Histology
For the histological part of the study, the surgical preparation 
and treatment were the same as described above (n = 5 
per group). After the 30-minute recovery, 5 mL/kg of 2% 
Evans blue (EB) dye, dissolved in saline, was administered 
intravenously at 0.1 mL/min. CSD waves were evoked by 
the same method as described above. Two additional animals 
served as sham-operated controls. The sham preparation was 
similar to that for experimental animals except that a saline-
impregnated cotton ball was applied to the cortex. After 1 hour 
induction of CSD by KCl or saline irrigation, the animals were 
perfused with cold saline and fixed with 4% paraformaldehyde 
dissolved in 0.1 M phosphate buffer. The brains were removed 
and postfixed overnight in the same paraformaldehyde solution. 
Sections were cut at a thickness of 20 µm with a vibratome 
(Leica VT 1000S; Leica Microsystems, Wetzlar, Germany). 
Twelve sections were cut in steps of 500 µm from the area of 
CSD initiation, in the rostral direction. The first section was 
situated 6 mm caudally from the bregma. These preparations 
were mounted on 2% gelatine-coated slides and covered with 
Fluoromount (SERVA, Heidelberg, Germany). The slides 
were examined under a fluorescent microscope (Olympus 
BX51; Olympus Corporation, Tokyo, Japan) equipped with 
a DP70 digital imaging system (Olympus Corporation). 
A Texas red filter (532–587 nm excitation wavelength and 
608–683 nm emission wavelength) was used for the detection 
of EB fluorescence. Two 1360 × 1024 red, green, blue color 
model  pictures were captured from each hemisphere of the 
sections (Figure 1). After data collection, the pictures were 
transformed to 8-bit gray-scale images, and the mean intensity 
was calculated via the following equation:
 I
n
j¯ 1=  
⋅
==
I
m
ij
m
i
n
1
∑∑
 
 (1)
where I is the intensity of pixels, n is the number of pixels in 
a row and m is the number of pixels in a column. After quan-
tification, the ratio of the intensities of the two hemispheres 
was calculated and plotted (Figure 2). Repeated-measures 
one-way analysis of variance (ANOVA) was carried out 
with Origin 8.1 software.
Results
Electrophysiology
KCl administration to the cortex resulted in CSD waves with 
a frequency of 15 ± 1.1/hour (mean ± standard error of the 
mean). KYNA suppressed the CSD activity significantly 
(9.8/hour ± 0.9/hour; P = 0.0084), while MK-801 administra-
tion completely eliminated the CSD waves (Figure 3A).
Detailed data analysis showed that the application of 1 M 
KCl to the cortex in the control group resulted in CSD waves 
with an amplitude of 21 mV ± 0.3 mV. However, KYNA 
(20.6 mV ± 0.7 mV) did not cause a significant change in the 
amplitude of the CSD waves, and no CSD wave was observed 
following the administration of MK-801 (Figure 3B).
Though KYNA did not induce a significant change in 
the amplitude of the CSD waves, the time at half-amplitude 
was significantly shorter after KYNA administration (from 
24.9 seconds ± 0.7 seconds to 21.7 seconds ± 0.6 seconds; 
P = 0.0014) (Figure 3C). This is because the CSD waves 
became sharper as compared with the controls after drug 
administration (Figure 4).
After integration of the waves, the CSD area in the con-
trol group was 48.3 ± 1.7. The KYNA treatment produced 
a significant decline, to 40.1 ± 2.4 (P = 0.008). MK-801 
completely eliminated the CSD activity (Figure 3D).
Histology
There were no detectable differences between the two hemi-
spheres after 1 hour of saline irrigation in the sham-operated 
control group (n = 2). In all groups, KCl was administered to 
the cortex, as detailed above. In the control and the KYNA-
treated group, massive plasma extravasation was detected 
as intense EB fluorescence within 1000 µm of the site of 
KCl application (Figure 2, 5). The only exception was the 
MK-801 group, where the level of fluorescence (extravasa-
tion) was half that in the control and KYNA groups. However, 
the intensity of fluorescence decreased with increasing 
distance from the site of CSD induction. Fluorescence in 
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the KYNA-treated animals was only reduced to the levels 
observed with MK-801 treatment at ∼1500 µm (Figure 2). 
Repeated-measures one-way ANOVA did not reveal any 
significant difference between the groups.
Discussion
The mechanism of generation of CSD waves, and especially 
those aspects relating to pathological conditions such as 
migraine, brain ischemia, and alterations in the BBB, is not 
yet clear.
A decade ago, it was reported that ischemia and hypoxic 
cortical depolarization are associated with an intense vasospasm 
and vasogenic edema.19 It was later found that neuronal and glial 
depolarization and an increase in extracellular glutamate level 
initiate a cascade that disrupts the BBB in numerous ways.6,7
We have previously investigated the effects of kynure-
nines on different animal models of migraine. In all of the 
studied models, KYN (a precursor of KYNA) and other 
KYNA derivatives proved effective in mitigating the 
stimulation-induced increase in c-fos immunoreactivity in 
the caudal trigeminal nucleus12,13 or nitroglycerine-induced 
neuronal nitric oxide synthase.14
It was recently described that the administration of KYN 
significantly decreases the frequency of CSD, an effect due 
to the increased level of KYNA in the brain.15 Although 
KYN seems to be neuroprotective in many animal models 
of migraine and stroke, it sometimes facilitates pathological 
pathways (our unpublished data).22 This may be caused by the 
metabolization of KYN; it can be converted to excitotoxic 
3-hydroxy-L-kynurenine and quinolinic acid in the brain.23 
Kynurenine aminotransferase converts KYN to KYNA in a 
unidirectional manner, and peripherally administered KYNA 
can therefore not be metabolized to excitotoxic agents.24 
Accordingly, and in light of the fact that CSD increases the 
permeability of the BBB, it appeared worthwhile to inves-
tigate whether systemically administered KYNA influences 
the CSD activity. In parallel with KYNA, we studied the 
effects of MK-801 as a positive control.
The aims of this study were to learn whether or not 
peripherally administered KYNA is able to influence the CSD 
activity, and whether these neuroactive molecules (which 
influence the glutamatergic system) act in parallel on CSD 
and the permeability of the BBB. Our results using these 
molecules were in accordance with earlier observations and 
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Figure 2 Fluorescence intensity changes caused by plasma extravasation in the three groups.
Notes: Each dot represents a mean intensity ratio (± standard error of the mean) of ten pictures, which were taken from the two hemispheres at the same distance from 
the KCl application area. There was no significant difference between the groups according to repeated-measures one way ANOVA.
Abbreviations: ANOVA, analysis of variance; CSD, cortical spreading depression; KYNA, kynurenic acid; MK-801, dizocilpine; KCl, potassium chloride.
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Figure 4 Representative cortical spreading depression (CSD) waves recorded in the barrel cortex.
Notes: The uppermost measurement is from a phosphate buffer-treated animal. The CSD wave frequency and the time at half-amplitude were reduced by kynurenic acid 
(KYNA) treatment, as shown by the second registration. Dizocilpine (MK-801) completely blocked the initiation of the waves. Scale bar: 1 minute; 5 mV.
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Figure 3 Diagrams of cortical spreading depression (CSD) wave parameters.
Notes: (A) Box diagrams of CSD frequency. The squares inside the boxes indicate the means of the samples. CSD frequency expressed in waves per hour. A significant 
difference between the control and the kynurenic acid (KYNA)-treated group was indicated by the two-sample t-test. **P , 0.01. Dizocilpine (MK-801) completely blocked 
the CSD waves. (B) CSD wave amplitudes in mV. No significant difference was detected by two-sample t-test. (C) Time at half-amplitude in seconds. Two-sample t-test 
was performed (**P , 0.01) between the control and treated group. (D) Diagram of CSD area. Two-sample t-test was performed (**P , 0.01) between the control and 
kynurenic acid (KYNA) groups.
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inferences that glutamate is involved in CSD.25,26 Results of 
this study also implicated elements of the pathophysiology 
of the disorder, including trigeminovascular activation and 
central sensitization.27
The fluorescent dye EB binds to the serum albumin in 
the blood. Under physiological conditions, albumin cannot 
pass through the brain capillaries. The intracellular calcium 
concentration [Ca2+]
i
 demonstrates a laminar difference in the 
response of the pyramidal neurons to CSD.28 Unfortunately, 
the situation concerning the [Ca2+]
i
 in the endothelial cells 
is not known, but in general, the linkage between [Ca2+]
i
, 
nitrous oxide, and the integrity of the BBB is well-based:29,30 
elevated [Ca2+]
i
 and enhanced neuronal nitric oxide synthase 
activation lead to robust vasodilatation and protein extravasa-
tion, when the albumin-EB complex may appear in the brain 
tissue following KCl-induced CSD activity.
Although it cannot be excluded that KCl administration 
itself may result in increased extravasation, the fact that 
KYNA and MK-801 administration resulted in reduced or 
eliminated CSD activity in parallel with decreased extravasa-
tion strongly suggests that the waves of cortical depolariza-
tion and the level of BBB permeability are related.
CSD waves, the typical electrophysiological signs of 
cortical depolarizing waves, disappeared completely after 
MK-801 administration. A similar, but less pronounced 
effect was observed after KYNA administration. The 
changes in the electrical signal of the CSD (ie, the decrease in 
frequency of the DC shifts and the sharpening of the waves) 
were observed at the beginning of recording, but CSD was 
elicited only at the beginning of the DC-ECoG measurement. 
This suggests that peripherally administered KYNA is able 
to cross the intact BBB and change the parameters of the 
waves. In parallel with the electrophysiological results, the 
administration of these NMDAR antagonists resulted in a 
gradually declining level of fluorescence, in accordance with 
increasing distance from the source of the CSD waves (the 
site of KCl application).
The reason for this relatively moderate effect of KYNA, 
as compared with that of MK-801, is probably its increased 
but limited permeability through the BBB. Under physi-
ological conditions, KYNA is barely able to cross the BBB,16 
but our results indicate that, in KCl-treated animals, KYNA 
may pass through the BBB and influence the CSD activity. 
KYNA presumably mitigates the effects of the glutamate 
system. KYNA is not only an endogenous NMDAR blocker, 
but also a noncompetitive inhibitor of the α-7-nicotinic ace-
tylcholine receptor,31,32 and through this mechanism, KYNA 
can decrease glutamate release.33 In this manner, KYNA can 
reduce the pathological glutamate level in the cortex during 
CSD activity and protect the BBB structure.6
Our results suggest that, in the course of CSD-induced 
glutamate release, the permeability of the BBB increases, 
and systemically administered KYNA can therefore reduce 
the consequences of CSD.
Recent findings indicated that kynurenines, and par-
ticularly KYNA, exhibit a strong modulatory potential on 
the neuronal structures in the brainstem, which may play a 
crucial role in the pathogenesis of migraine.34 The present 
data reveal that KYNA may also act in the cortex. These 
results provide an experimental tool by which to understand 
the pathomechanism of migraine. However, further studies 
are needed to clarify the possible role of the kynurenines in 
the therapy of migraine.
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